Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSET: Sunitinib Schedule Comparison in Metastatic RCC
NCT03109015Phase 2Completed
- Sponsor
- Duke University
- Start
- Sep 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in renal cell carcinoma (RCC), sponsored by Duke University. Started Sep 2017; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03109015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109015.